Boniva ibandronate regulatory update

Chugai submitted an NDA in Japan for a monthly oral formulation of Boniva ibandronate to treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits osteoclast-mediated bone resorption in Japan (see BioCentury, Sept. 18, 2006). Chugai is majority owned by Roche. ...